![]() SignaBlok Awarded NIH NIDDK Grant to Develop Novel TREM-1 Antagonist Drug for Inflammatory Bowel DiseaseSignaBlok, Inc. has been awarded a Phase I SBIR grant from the NIH NIDDK to advance the development of a novel mechanism-based therapy for inflammatory bowel disease (IBD). The award supports SignaBlok's differentiated approach to targeting TREM-1 in IBD.
By: SignaBlok, Inc. SHREWSBURY, Mass. - Sept. 17, 2026 - PRLog -- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the National Institutes of Health (NIH), has awarded SignaBlok, Inc., a biopharmaceutical company focused on developing novel peptide antagonists of cell receptors, a Phase I Small Business Innovation Research (SBIR) grant to develop a new therapeutic approach for inflammatory bowel disease (IBD).
SignaBlok's approach to IBD therapy targets TREM-1, a cell-surface receptor that has emerged as a promising therapeutic target in inflammation. As an amplifier of inflammatory responses, TREM-1 is implicated in IBD, cancer, arthritis, retinopathy, fibrosis, and other inflammatory conditions. Of particular relevance to IBD, targeting TREM-1 delivers not only anti-inflammatory and inflammation- Two of SignaBlok's proprietary technologies will be utilized under the grant "New TREM-1 therapy for inflammatory bowel disease":
"This award from the NIDDK / NIH reinforces the promise of SignaBlok's core platform technologies," References:
About SignaBlok: SignaBlok, Inc. is a late preclinical stage biopharma company that develops first-in-class peptide-based TREM-1 and TREM-2 therapeutics, radiopharmaceuticals, companion diagnostics, and theranostics to address innate inflammation in multiple diseases. SignaBlok also specializes in targeted nanodelivery of SCHOOL peptides and other therapies and/or imaging agents. Additional information is available at www.signablok.com. End
Page Updated Last on: Sep 17, 2026
|